Reviewing SIGA Technologies Inc. (SIGA)’s and Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)’s results

SIGA Technologies Inc. (NASDAQ:SIGA) and Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SIGA Technologies Inc. 476.90M 1.11 359.11M 4.31 1.43
Corvus Pharmaceuticals Inc. N/A 0.00 48.36M -1.97 0.00

Demonstrates SIGA Technologies Inc. and Corvus Pharmaceuticals Inc. earnings per share, gross revenue and valuation.


Table 2 shows us SIGA Technologies Inc. and Corvus Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
SIGA Technologies Inc. 75.30% -151.7% 261.2%
Corvus Pharmaceuticals Inc. 0.00% -41.3% -38%


The Current Ratio and Quick Ratio of SIGA Technologies Inc. are 21.8 and 21.3 respectively. Its competitor Corvus Pharmaceuticals Inc.’s Current Ratio is 16.1 and its Quick Ratio is 16.1. SIGA Technologies Inc. can pay off short and long-term obligations better than Corvus Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both SIGA Technologies Inc. and Corvus Pharmaceuticals Inc. are owned by institutional investors at 20.9% and 87.6% respectively. About 1.9% of SIGA Technologies Inc.’s share are owned by insiders. Competitively, Corvus Pharmaceuticals Inc. has 5.08% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
SIGA Technologies Inc. -1.6% 18.76% -12.91% -13.28% 27.39% 26.6%
Corvus Pharmaceuticals Inc. -2.68% -26.33% -45.35% -54.81% -45.51% -43.82%

For the past year SIGA Technologies Inc. has 26.6% stronger performance while Corvus Pharmaceuticals Inc. has -43.82% weaker performance.


On 9 of the 10 factors SIGA Technologies Inc. beats Corvus Pharmaceuticals Inc.

SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.